Eribulin long-term response and rechallenge: report of two clinical cases.

about

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.

P2860

Q55342871-14C115CB-E990-43E6-AE14-0D6F15E942F5

P2860

Eribulin long-term response and rechallenge: report of two clinical cases.

Item

http://www.wikidata.org/entity/Q38686613

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Eribulin long-term response and rechallenge: report of two clinical cases.

@en

type

Item

label

Eribulin long-term response and rechallenge: report of two clinical cases.

@en

prefLabel

Eribulin long-term response and rechallenge: report of two clinical cases.

@en

P1476

Eribulin long-term response and rechallenge: report of two clinical cases.

@en

P2093

Angela Fini

http://www.w3.org/2001/XMLSchema#string

Claudio Zamagni

http://www.w3.org/2001/XMLSchema#string

Daniela Rubino

http://www.w3.org/2001/XMLSchema#string

Elena Barbieri

http://www.w3.org/2001/XMLSchema#string

Manuela Lenzi

http://www.w3.org/2001/XMLSchema#string

Rossella Hakim

http://www.w3.org/2001/XMLSchema#string

P2860

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer

Global cancer statistics, 2012

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

Drug rechallenge and treatment beyond progression--implications for drug resistance.

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.

Maintenance treatment in metastatic breast cancer.

P304

35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0520

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

11s

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28481188

http://www.w3.org/2001/XMLSchema#string

Eribulin long-term response and rechallenge: report of two clinical cases.

about

P2860

P2860

Eribulin long-term response and rechallenge: report of two clinical cases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698